ENT1和DCK基因的高表达水平是预测T细胞急性淋巴细胞白血病对奈拉滨治疗产生良好反应的潜在生物标志物。 - Suppr | 超能文献

相似文献

1

High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia.ENT1和DCK基因的高表达水平是预测T细胞急性淋巴细胞白血病对奈拉滨治疗产生良好反应的潜在生物标志物。

Hematol Oncol. 2019 Oct;37(4):516-519. doi: 10.1002/hon.2654. Epub 2019 Aug 2.

2

Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.基因表达比率作为T淋巴细胞母细胞白血病/淋巴瘤中奈拉滨化疗敏感性的预测决定因素。

Pediatr Blood Cancer. 2017 Feb;64(2):250-253. doi: 10.1002/pbc.26214. Epub 2016 Aug 31.

3

In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.体外研究氟达拉滨和奈拉滨（ara-G）在儿科白血病中的疗效。

Blood. 2011 Aug 25;118(8):2184-90. doi: 10.1182/blood-2011-02-337840. Epub 2011 Jul 5.

4

Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.白血病细胞系对奈拉滨耐药可能是由于脱氧胞苷激酶通过表观遗传机制表达减少所致。

Cancer Chemother Pharmacol. 2022 Jan;89(1):83-91. doi: 10.1007/s00280-021-04373-4. Epub 2021 Nov 26.

5

SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.SAMHD1是急性淋巴细胞白血病对奈拉滨的谱系特异性反应的关键调节因子。

Commun Biol. 2020 Jun 24;3(1):324. doi: 10.1038/s42003-020-1052-8.

6

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.CD123 表达模式及 CD123 靶向抗体药物偶联物（IMGN632）在急性淋巴细胞白血病中的选择性靶向作用。

Haematologica. 2019 Apr;104(4):749-755. doi: 10.3324/haematol.2018.205252. Epub 2018 Oct 25.

7

A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.耐奈拉滨的 T 淋巴细胞白血病 CCRF-CEM 变异细胞系对嘌呤核苷磷酸化酶抑制剂氟达拉滨也有交叉耐药性。

Anticancer Res. 2014 Sep;34(9):4885-92.

8

Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.纳拉滨用于治疗复发或难治性 T 细胞急性淋巴细胞白血病或淋巴母细胞淋巴瘤的患者。

Hematol Oncol Clin North Am. 2009 Oct;23(5):1121-35, vii-viii. doi: 10.1016/j.hoc.2009.07.008.

9

Malignancy-Associated Hypercalcemia Related with Receptor Activator of NF-κB Ligand (RANKL) Expression in T-Cell Acute Lymphoblastic Leukemia.与T细胞急性淋巴细胞白血病中核因子κB受体活化因子配体（RANKL）表达相关的恶性肿瘤相关性高钙血症

Acta Haematol. 2019;141(3):135-137. doi: 10.1159/000495741. Epub 2019 Feb 15.

10

Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.药物掺入DNA减少和抗凋亡作为一种新型奈拉滨耐药细胞系耐药的关键机制。

BMC Cancer. 2014 Jul 29;14:547. doi: 10.1186/1471-2407-14-547.

引用本文的文献

1

Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action.奈拉滨用于T细胞急性淋巴细胞白血病：细胞内代谢及分子作用机制

Leukemia. 2025 Mar;39(3):531-542. doi: 10.1038/s41375-025-02529-2. Epub 2025 Feb 17.

2

Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response.药物转运体在阐释儿童化疗相关毒性和反应个体间差异中的作用

Pharmaceuticals (Basel). 2022 Aug 11;15(8):990. doi: 10.3390/ph15080990.

3

SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.